CDK4 and breast cancer: Here, we assess the biological changes that occur upon CDK4/6 inhibition in breast cancer cell lines and clinical samples of patients who participated in two neoadjuvant phase II studies of ribociclib or palbociclib in combination with endocrine therapy.